SOLICITATION NOTICE
A -- Staged Vaccine Development
- Notice Date
- 1/22/2013
- Notice Type
- Presolicitation
- NAICS
- 541712
— Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Office of Acquisitions, 6700 B Rockledge Room 3214 MSC7612, Bethesda, Maryland, 20892-7612
- ZIP Code
- 20892-7612
- Solicitation Number
- BAA-NIAID-DAIDS-NIHAI2012151
- Archive Date
- 2/20/2013
- Point of Contact
- George Keane, Phone: 3014513690, Michelle L Scala, Phone: 301-496-0612
- E-Mail Address
-
george.keane@nih.gov, mscala@niaid.nih.gov
(george.keane@nih.gov, mscala@niaid.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- The Division of Acquired Immune Deficiency Syndrome (DAIDS) of the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), is committed to the development of efficacious preventive vaccines against HIV-1 for worldwide use to end the AIDS epidemic. While industry, government, and academia have contributed considerable resources to this effort over the past 30 years, no fully effective vaccine has emerged. A wide assortment of candidate HIV-1 vaccines have reached Phase I clinical trials but only three vaccine regimens have advanced to efficacy testing. One of these 3 trials, designated RV144, has shown modest efficacy in humans and this result coupled with promising results from nonhuman primate (NHP) studies has now stimulated the field to continue to test more advanced vaccine candidates in humans. Thus, the discovery and development, of preventive HIV/AIDS vaccines may be within reach. To augment the development portion of the process for identifying and ultimately testing an improved HIV vaccine, NIAID will be using a staged development approach to allow the rapid advancement of promising HIV vaccine candidates to CGMP manufacturing for subsequent clinical testing. The primary intent of this Broad Agency Announcement (BAA) solicitation is to provide support to multifunctional teams for advanced development and manufacture of HIV vaccines candidates that have demonstrated success in NHP challenge studies, equivalent preclinical animal models or early human clinical trials, and have demonstrated manufacturing feasibility. The activities supported through this BAA will allow the further development of the current leading HIV vaccine candidates, based on existing data are defined below (the areas listed below are the primary areas of interest of this BAA, but not limited exclusively to these areas when submitting proposals): •Recombinant HIV protein including HIV envelopes, envelope derivatives, Virus Like Particles, as well as formulations of HIV proteins with immune enhancers such as adjuvants and immune modulators. •POX virus (e.g. Fowlpox, NYVAC, ALVAC, Modified Vaccinia Ankara (MVA) vector-based vaccine candidates. •DNA vaccines, including DNA delivery device technologies and DNA expressed immune modulators. •Replication defective adenovirus vectors with low sero-prevelence in the relevant human population. •Replication competent viral vectors (e.g. Flaviviridae, Adenoviridae, Alphaherpesvirinae, Rhabdoviridae.) Awards will be based on evaluation of the potential to advance the vaccine candidates forward through a staged approach. This staged approach will allow NIAID flexibility to quickly advance vaccine candidates into milestone drive CGMP manufacturing for testing in clinical trials. Briefly, the 3 stages are as follows: •Stage I- refinement and implementation of the product development plan and the initiation of limited activities to prepare for the CGMP production of the vaccine candidate; •Stage II- manufacture, formulation, and release of the product for phase I/II/III clinical trials; and •Stage III- continuation of ongoing stability program, pre-licensure activities, continued product characterization studies, and updated regulatory submissions that would allow the product to remain in regulatory compliance and acceptable for future clinical trials. Each contract will be awarded for up to a two year base period to support Stage I activities and will include two options for Stage II and Stage III activities. Options for Stage II and III awards will be exercised based on Go/No Go decisions. Once Stage I milestones are met the decision to fund the option for Stage II will depend upon the scientific priority, program balance, and the availability of funds. Likewise, the funding of the option for Stage III will depend on meeting Stage II milestones, as well as scientific priority, program balance, and the availability of funds. All activities must be performed in strict adherence to FDA regulations and guidance, including requirements for manufacturing of the vaccine candidate under CGMP (21 CFR 11, 210, 211, 600-680, and 820) and the conduct of animal studies and assays under GLP (21 CFR 58). It is anticipated that 4 to 6 contracts will be awarded beginning on or about July 1, 2014. NIAID plans to use a staged funding approach. The contract will be awarded for up to a 2 year base period to support Stage I activities and will include two options for Stage II and Stage III activities. Below are the estimated cost and period of performance of each Stage: Stage I: Approximately $100,000/year for a maximum performance period of up to 2 years Stage II: Approximately $5,000,000/year for a maximum performance period of 3 years Stage III: Approximately $1,000,000/year for a maximum performance period of 2 years All responsible sources may submit a proposal which shall be considered by the Agency. This BAA will be available electronically on/about February 5, 2013 and may be accessed through FedBizOpps http://www.fedbizopps.gov/. This notice does not commit the Government to award a contract. No collect calls will be accepted. No facsimile transmissions will be accepted.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NIAID/BAA-NIAID-DAIDS-NIHAI2012151/listing.html)
- Record
- SN02970036-W 20130124/130122234400-78dcd9f040d27e3240f7237b748d8b06 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |